Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | F10 | P00742 | 1/20 | 0.51 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.49 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.49 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.49 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.47 |
| ▸ | DHODH | Q02127 | 1/20 | 0.47 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2894211 | 0.88 | GRIK1 (0.56) | GAANPC1RAB9AMEN1KMT2A | |
| SCHEMBL19554286 | 0.81 | GAA (0.60) | GAANPC1RAB9AMEN1KMT2A | |
| SCHEMBL18118626 | 0.80 | KDM4E (0.68) | GAANPC1RAB9AMEN1KMT2A | |
| SCHEMBL1307456 | 0.79 | GRIK1 (0.67) | MEN1KMT2AF10GRIK1GRIK2 | |
| SCHEMBL3280717 | 0.77 | EGFR (0.50) | NPC1RAB9AMEN1KMT2AGRIK1 | |
| SCHEMBL3280709 | 0.77 | EGFR (0.50) | NPC1RAB9AMEN1KMT2AGRIK1 | |
| SCHEMBL28466857 | 0.77 | ALDH1A1 (0.70) | GAANPC1RAB9AMEN1KMT2A | |
| SCHEMBL6232372 | 0.75 | NPC1 (0.69) | NPC1RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL5381583 | 0.73 | DNM2 (0.56) | GAANPC1RAB9AMEN1KMT2A | |
| SCHEMBL3964585 | 0.72 | GRIK1 (0.67) | GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286149-A1 | NOVEL BENZAMIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-11-11 | — | — | US | claimed |
| EP-2212303-A1 | NOVEL BENZAMIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | NeuroSearch AS (DK) | 2010-08-04 | — | — | EP | claimed |
| WO-2009068509-A1 | NOVEL BENZAMIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2009-06-04 | — | — | WO | claimed |
| US-20100286149-A1 | NOVEL BENZAMIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-11-11 | — | — | US | disclosed |
| EP-2212303-A1 | NOVEL BENZAMIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | NeuroSearch AS (DK) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009068509-A1 | NOVEL BENZAMIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286149-A1 | NOVEL BENZAMIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | KCNA2, KCNJ2, KCNB2 | GAA 1524/4885NPC1 1201/4885RAB9A 1720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.